# BLIND POINT-IN-TIME FORECASTING TASK
You are a professional regulatory forecaster. This file contains 20 independent forecasting snapshots about
DIFFERENT regulatory matters. Treat each snapshot on its own; do not carry information between snapshots.

Rules:
1. For each snapshot, "today" is its CUTOFF DATE. Use only the evidence shown plus general knowledge of how the
   regulatory process usually behaves (base rates, typical durations). Do not use any world-state fact learned after
   the cutoff: later election results, leadership changes, court rulings, agency decisions, dates or outcomes are
   unknown, even if you remember them. A future event stated in cutoff-valid evidence may be considered only as an
   uncertain plan or possibility, never as a later-known result. Every factual driver in "notes" or "scenarios" must
   be supported by the shown evidence or be a general process base rate.
2. Do NOT use any specific memory of what happened to this particular matter after the cutoff. If you recognise the
   matter and believe you know its later outcome, set "recognised_outcome": true and forecast from cutoff-valid
   evidence only. Never state or hint at the remembered result.
3. The evidence shown may be only a subset of what was public; do not infer anything from the absence of a
   document type. Some snapshots show no documents at all — then forecast from title, regulator, process and date.
4. "Decisive action" is defined per snapshot. Probabilities in "p" are CUMULATIVE: probability the decisive action
   is published within 7/30/60/90/180 days AFTER the cutoff (non-decreasing; "180d" is the headline action
   probability). Delays, stalls, withdrawals and no-action outcomes are common in regulation: be calibrated, use
   the full 0–1 range when evidence warrants, and do not default to 0.5.
5. "next": the NEXT official step within 180 days (mutually exclusive, sums to 1): final_action,
   revised_or_further_consultation (revised draft, supplemental proposal, extended/reopened comment period,
   further consultation or hearing), formal_withdrawal, no_further_official_step.
6. "content": CONDITIONAL on the decisive action happening, its form relative to the most recent proposal visible
   (sums to 1): as_proposed (substantially as proposed), softened (narrower scope, lower stringency, higher
   thresholds, longer transition, carve-outs), tightened, mixed (some softened, some tightened),
   different_mechanism.
7. "scenarios": up to 3 concrete policy-content scenarios CONDITIONAL on action (probabilities sum ≤ 1), each with
   a short mechanism and, where the evidence has numbers (thresholds, rates, dates, amounts), predicted
   parameter ranges. Cite evidence labels (E1, E2 …) that support/contradict it.
8. If the evidence is too thin to forecast meaningfully, set "insufficient_evidence": true but still give your best
   base-rate probabilities.

OUTPUT: read the output file named in your instructions (it contains a placeholder) and replace its ENTIRE content
with ONE JSON object of exactly this shape (no comments, no trailing text):
{"forecasts": [
  {"id": "<snapshot id>",
   "p": {"7d": 0.00, "30d": 0.00, "60d": 0.00, "90d": 0.00, "180d": 0.00},
   "next": {"final_action": 0.00, "revised_or_further_consultation": 0.00, "formal_withdrawal": 0.00, "no_further_official_step": 0.00},
   "content": {"as_proposed": 0.00, "softened": 0.00, "tightened": 0.00, "mixed": 0.00, "different_mechanism": 0.00},
   "scenarios": [{"s": "short label", "p": 0.00, "mech": "mechanism, <=25 words", "params": {"parameter": "predicted range"}, "ev": ["E1"], "contra": []}],
   "notes": "<=40 words: main drivers of your forecast",
   "missing": ["<=3 items of missing information that would most change the forecast"],
   "recognised_outcome": false,
   "insufficient_evidence": false}
]}
One entry per snapshot, in any order, using the exact snapshot ids below.

---
## SNAPSHOT Sb59f09546a
CUTOFF DATE (today): 2021-10-27
Regulator: FDA (US)
Matter: FDA draft guidance: Patient Engagement in the Design and Conduct of Medical Device Clinical Investigations
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S519d977f04
CUTOFF DATE (today): 2023-02-24
Regulator: FDA (US)
Matter: FDA draft guidance: Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Scb45011ca1
CUTOFF DATE (today): 2024-05-30
Regulator: FDA (US)
Matter: FDA draft guidance: Voluntary Malfunction Summary Reporting Program for Manufacturers
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2022-12-09 | official-forward (B) | draft_guidance_availability_notice | "Voluntary Malfunction Summary Reporting Program for Manufacturers; Draft Guidance for Industry and Food and Drug Administration Staff; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled "Voluntary Malfunction Summary Reporting (VMSR) Program for Manufacturers." We are publishing this notice of availability for this draft guidance document to help manufacturers better under
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled "Voluntary Malfunction Summary Reporting (VMSR) Program for Manufacturers." We are publishing this notice of availability for this draft guidance document to help manufacturers better understand and use the VMSR Program. It is intended to further explain, but not change, the conditions of the VMSR Program. This draft guidance is not final nor is it for implementation at this time.
---
## SNAPSHOT S872fabc935
CUTOFF DATE (today): 2023-05-30
Regulator: FDA (US)
Matter: FDA draft guidance: Chronic Rhinosinusitis With Nasal Polyps: Developing Drugs for Treatment
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S6ee8b3e3ca
CUTOFF DATE (today): 2026-05-16
Regulator: SEBI (IN)
Matter: SEBI consultation: reviewing base price and price band methodology for Exchange Traded Funds
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-02-13 | official-forward (B) | consultation_paper | "Consultation Paper on Review of provisions related to Base Price and Price Bands for Exchange Traded Funds (ETFs)" | www.sebi.gov.in
   Claims: Seeks public comments on proposals to revise the base price and price-band methodology specifically for Exchange Traded Funds (equity, debt and commodity ETFs including Gold/Silver ETFs). / Notes the current fixed price band of +/-20% (+/-5% for Overnight ETFs) is applied to a base price equal to the T-2 day NAV of the ETF, creating a one-trading-day lag. / Frames the issue as the fixed band and NAV lag not being commensurate with the price range of the ETF's underlying assets.
   Excerpt: The objective of this consultation paper is to seek public comments on the proposals on Base Price and Price Bands for Exchange Traded Funds (ETFs). ETF is a mutual fund scheme that invests in securities in the same proportion as an index of securities and the units of exchange traded fund are mandatorily listed and traded on exchange platform... Currently, there are individual scrip wise price bands of up to 20% either way, applicable for all scrips in the rolling settlement except for the scrips on which derivatives products are available.
---
## SNAPSHOT S0e9bc218df
CUTOFF DATE (today): 2026-06-12
Regulator: SEBI (IN)
Matter: SEBI consultation: recognizing intraday borrowing facilities as a cash-management tool for mutual funds
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sc5b58156b6
CUTOFF DATE (today): 2024-07-14
Regulator: FDA (US)
Matter: FDA draft guidance: Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S98026427cb
CUTOFF DATE (today): 2026-05-28
Regulator: SEBI (IN)
Matter: SEBI consultation: phased introduction of physical settlement in select agricultural commodity derivatives contracts
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-05-12 | official-forward (B) | consultation_paper | "Consultation Paper on 'Phased Introduction of Physical Settlement in Select Agricultural Commodity Derivatives Contracts'" | www.sebi.gov.in
   Claims: Proposes to permit exchanges, on a pilot basis, to launch delivery-based agricultural commodity derivatives contracts that start as financially-settled and mandatorily convert to physical settlement upon crossing predefined objective thresholds. / States the proposal does not dilute the principle of physical settlement; contracts remain designed as delivery-based instruments from inception, with the financially-settled phase only a temporary transitional arrangement. / Frames the review against the backdrop that compulsory physical settlement from contract inception may inhibit early liquidity formation and participation. / Notes agricultural commodity derivatives in India have historically emphasized physical settlement to ensure futures-spot price convergence and discourage excessive speculation.
   Excerpt: This consultation paper seeks stakeholder views on a proposal to permit exchanges, on a pilot basis, to introduce delivery-based agricultural commodity derivatives contracts that commence trading as financially-settled contracts and mandatorily transition into physically settled contracts upon the occurrence of predefined objective thresholds. Commodity derivatives markets play a vital role in the efficient functioning of agricultural value chains by facilitating price discovery, risk management, and market transparency.
---
## SNAPSHOT Safe94de614
CUTOFF DATE (today): 2025-11-17
Regulator: SEBI (IN)
Matter: SEBI consultation: permitting debt issuers to offer incentives to certain categories of investors in public issues
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2025-10-27 | official-forward (B) | consultation_paper | "Consultation paper for permitting debt issuers to offer incentives in public issues to certain category of investors" | www.sebi.gov.in
   Claims: Proposes amending NCS Regulations, 2021 to allow debt issuers to offer incentives (additional interest or issue-price discount) to specified categories of investors in public debt issues. / Proposes the eligible categories include senior citizens, women, and serving/retired armed-forces personnel and their widows/widowers, plus retail individual investors. / States the incentive would apply only to the initial allottee and not survive transfer/transmission of the securities. / Frames the objective as boosting retail participation in the corporate debt market and encouraging public debt issuances.
   Excerpt: CONSULTATION PAPER, DEPARTMENT OF DEBT AND HYBRID SECURITIES, Consultation paper for permitting debt issuers to offer incentives in public issues to certain category of investors, October 2025.
---
## SNAPSHOT S0d0035a7a5
CUTOFF DATE (today): 2024-04-12
Regulator: FDA (US)
Matter: FDA draft guidance: Mpox: Development of Drugs and Biological Products
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2023-01-20 | official-forward (B) | draft_guidance_availability_notice | "Mpox: Development of Drugs and Biological Products; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Mpox: Development of Drugs and Biological Products." FDA is issuing this guidance to support sponsors in their development of drugs and biological products for mpox.
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Mpox: Development of Drugs and Biological Products." FDA is issuing this guidance to support sponsors in their development of drugs and biological products for mpox.
---
## SNAPSHOT Sb8cd3e8195
CUTOFF DATE (today): 2022-07-21
Regulator: FDA (US)
Matter: FDA draft guidance: Donor Eligibility for Animal Cells, Tissues, and Cell- and Tissue-Based Products
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S3fe0607c6a
CUTOFF DATE (today): 2026-09-17
Regulator: SEBI (IN)
Matter: SEBI consultation: harmonizing base price for pre-open call auction and price bands for stocks listed on multiple exchanges
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-06-11 | official-forward (B) | consultation_paper | "Consultation Paper on Harmonization of Base price for Call Auction in Pre-open Session and for Price Band - For scrips listed on multiple stock exchanges" | www.sebi.gov.in
   Claims: Seeks public comments on proposals to harmonize the base price for the pre-open call-auction session, and price bands, for scrips listed on more than one recognized stock exchange. / Notes existing rule (Master Circular Para 2.3) prescribing individual scrip-wise price bands of up to 20% either way for scrips without derivatives products. / Notes existing rule (Master Circular Para 17.1.6) that price bands in the pre-open session equal those applicable in the normal market. / Frames the issue as inconsistency that can arise when a scrip is listed on multiple exchanges, each of which may independently apply these base-price/price-band rules.
   Excerpt: The objective of this consultation paper is to seek public comments on the proposals to harmonize the base price for call auction in pre-open session and for setting up price bands for scrips listed on multiple stock exchanges. Background: As a measure against excessive price movements, SEBI vide circular No. SMDRPD/Policy/Cir-37/2001 dated June 28, 2001 has advised stock exchanges to implement individual scrip wise price bands of 20% either way, for all scrips in compulsory rolling settlement except for the scrips on which derivatives products are available or scrips included in indices on which derivatives products are available.
---
## SNAPSHOT Sf01d88151a
CUTOFF DATE (today): 2026-04-29
Regulator: SEBI (IN)
Matter: SEBI consultation: modifying nomination norms for demat accounts and mutual fund folios
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sec1551e69c
CUTOFF DATE (today): 2023-04-06
Regulator: FDA (US)
Matter: FDA draft guidance: Peripheral Percutaneous Transluminal Angioplasty and Specialty Catheters-Premarket Notification (510(k)) Submissions
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Seb27ba1de3
CUTOFF DATE (today): 2026-06-27
Regulator: SEBI (IN)
Matter: SEBI consultation: ease-of-doing-business modifications to master circular provisions on exchange traded derivatives
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT Safb7c51524
CUTOFF DATE (today): 2025-12-10
Regulator: SEBI (IN)
Matter: SEBI consultation: easing IPO lock-in mechanics for pledged shares and requiring an abridged prospectus at the draft-offer-document stage
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S7d743d9b36
CUTOFF DATE (today): 2026-08-25
Regulator: SEBI (IN)
Matter: SEBI consultation: enhancements to the Straight-Through Processing framework for institutional trade messaging
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S0849a50464
CUTOFF DATE (today): 2025-11-24
Regulator: SEBI (IN)
Matter: SEBI consultation: ease-of-doing-business modifications to master circular provisions on administration of stock exchanges
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S72e4ff6b0f
CUTOFF DATE (today): 2026-03-25
Regulator: FDA (US)
Matter: FDA draft guidance: International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations ...
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2022-08-11 | official-forward (B) | draft_guidance_availability_notice | "International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Caprines (Revision 1); Draft Guidance f" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry GFI #97 (VICH GL14(R1)) entitled "Effectiveness of Anthelmintics: Specific Recommendations for Caprines (Revision 1)." This draft guidance has been developed for veterinary use by the Int
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry GFI #97 (VICH GL14(R1)) entitled "Effectiveness of Anthelmintics: Specific Recommendations for Caprines (Revision 1)." This draft guidance has been developed for veterinary use by the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH). This revision clarifies the definition of adequate infection in individual animals, updates considerations for field studies, and makes additional clarifying changes.
---
## SNAPSHOT S6a712174ce
CUTOFF DATE (today): 2023-08-18
Regulator: FDA (US)
Matter: FDA draft guidance: Charging for Investigational Drugs Under an Investigational New Drug Application: Questions and Answers
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2022-08-23 | official-forward (B) | draft_guidance_availability_notice | "Charging for Investigational Drugs Under an Investigational New Drug Application: Questions and Answers; Revised Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry entitled "Charging for Investigational Drugs Under an IND: Questions and Answers." Since issuance of the final guidance in 2016, FDA has received questions from stakeholders throu
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry entitled "Charging for Investigational Drugs Under an IND: Questions and Answers." Since issuance of the final guidance in 2016, FDA has received questions from stakeholders through the docket and in the form of communications with review divisions. These questions relate to the implementation of FDA's regulation on charging for investigational drugs under an investigational new drug application (IND) for the purpose of either clinical trials or expanded access for treatment use. FDA is providing this revised draft guidance in a question-and-answer format, addressing the most recently asked questions. When finalized, this revised draft guidance will replace the final guidance of the same title issued in June 2016.